2 studies found for:    iCo-007
Show Display Options
Rank Status Study
1 Completed Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
Condition: Diffuse Diabetic Macular Edema
Intervention: Drug: iCo-007 Intravitreal Injection
2 Active, not recruiting A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
Condition: Diabetic Macular Edema
Interventions: Drug: iCo-007 350 mcg;   Drug: iCo-007 700 mcg;   Drug: iCo-007 350 mcg Plus Laser;   Drug: Ranibizumab Plus iCo-007 350 mcg

Indicates status has not been verified in more than two years